AstraZeneca
EPO rules Symbicort combination patent still valid
Published in Medicine and Law Weekly, April 8th, 2005
This positive decision means there will be no change in the validity of the patent for Symbicort, covering the combination of formoterol and budesonide in Austria, Belgium, Denmark, France, Germany, Greece, Ireland, Italy, Liechtenstein, Luxemburg, Monaco, the Netherlands, Portugal, Spain, Sweden, Switzerland, and the United Kingdom.
AstraZeneca has a comprehensive intellectual property portfolio including both patents and data exclusivity for Symbicort. Most major European...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medicine and Law Weekly
More Articles from Medicine and Law Weekly
- AIDS Healthcare Foundation
Legal order allows challenge to AIDS drug pricing in South African to go forward - Albert Einstein College of Medicine
Anti-CXCR4 antibodies differ significantly in ability to inhibit HIV entry - American College of Physician Executives
Survey showing unethical business practices in U.S. healthcare alarms physicians - Applied NeuroSolutions
Patent issued for Alzheimer blood test technology - Awards
Houston, Texas, attorneys named fellows of American Health Lawyers Association - Bio-Matrix Scientific Group, Inc.
Stem cell instruments patent filed with U.S. patent office - More from this issue of Medicine and Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
